Cognition Therapeutics (NASDAQ:CGTX) Raised to Hold at Wall Street Zen

Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

A number of other equities research analysts have also recently commented on CGTX. Chardan Capital restated a “buy” rating and set a $4.00 target price on shares of Cognition Therapeutics in a research note on Friday, August 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Cognition Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $2.83.

Cognition Therapeutics Stock Performance

Shares of CGTX stock remained flat at $1.66 during trading hours on Friday. 1,029,681 shares of the stock traded hands, compared to its average volume of 1,371,319. The firm has a market cap of $122.05 million, a PE ratio of -3.46 and a beta of 1.23. The stock has a 50-day moving average price of $1.78 and a two-hundred day moving average price of $1.07. Cognition Therapeutics has a 1 year low of $0.22 and a 1 year high of $3.83.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. On average, equities research analysts forecast that Cognition Therapeutics will post -0.8 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jones Financial Companies Lllp acquired a new stake in shares of Cognition Therapeutics in the third quarter valued at about $25,000. Northeast Financial Consultants Inc grew its position in Cognition Therapeutics by 158.6% in the first quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company’s stock worth $27,000 after acquiring an additional 38,851 shares during the period. CWA Asset Management Group LLC acquired a new stake in shares of Cognition Therapeutics during the 3rd quarter worth about $34,000. Everhart Financial Group Inc. purchased a new stake in shares of Cognition Therapeutics in the 3rd quarter valued at approximately $43,000. Finally, Bryn Mawr Trust Advisors LLC lifted its stake in Cognition Therapeutics by 69.1% during the third quarter. Bryn Mawr Trust Advisors LLC now owns 39,466 shares of the company’s stock worth $53,000 after purchasing an additional 16,129 shares in the last quarter. Hedge funds and other institutional investors own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.